Patients harboring cancers with FGF/FGFR pathway gene alterations accompanied by TP53 pathway or cell cycle pathway alterations had worse overall survival compared to patients with FGF/FGFR-altered cancers without those co-alterations. The gene discussed is TP53; the disease is cancer.